Published: 6 July 2020
Author(s): Ilaria M. Saracino, Matteo Pavoni, Angelo Zullo, Giulia Fiorini, Laura Saccomanno, Tiziana Lazzarotto, Guido Antonelli, Rossana Cavallo, Claudio Borghi, Dino Vaira
Section: Original article

H. pylori causes chronic gastritis and peptic ulceration, and concurs to gastric MALT lymphoma and carcinoma development [1]. Treatment of the infection remains a challenge for clinicians, as no therapeutic regimen is 100% effective. Although there are several factors influencing efficacy of H. pylori therapy, resistance to antibiotics remains the most relevant [2,3]. There is evidence that the efficacy of standard first-line and second-line therapies is decreasing in most countries. Moreover, curing the infection in eradication failure patients is progressively more difficult.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.